FORM D

Notice of Exempt Offering of Securities

Yet to Be Formed

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL	
OMB Number: 3235-0076	
Expires: June 30, 2012	
Estimated Average burden hour per response: 4.0	s

T. Issuer's identity			
CIK (Filer ID Number)	Previous Name(s)	Mone None	Entity Type
0001582554]		Corporation
Name of Issuer	-		Limited Partnership
Matinas BioPharma Holdings, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Organization			General Partnership
DELAWARE]		Business Trust
Year of Incorporation/Organization	n		Other
 □ Over Five Years Ago Within Last Five Years (Specify Year))13		

2. Principal Place of Business and Contact Information

Name of Issuer					
Matinas BioPharma Holdings,	Inc.				
Street Address 1		Stre	eet Address 2		
600 W. GERMANTOWN PIKE		S	JITE 400		
City	State/Province/Countr	у	ZIP/Postal Code	Phone No. of Issuer	
PLYMOUTH MEETING	PENNSYLVANIA		19462	610-771-0680	

3. Related Persons

Last Name		First Name			Middle	Name	
HARRINGTON		STEPHEN			Р		
Street Address 1			e L	Street Address 2			
600 W. GERMANTO	WN PIKE			SUITE 400			
City		State/Province/	Coun	try	ZIP/Pos	stal Code	
PLYMOUTH MEETING PENNSY		PENNSYLV	PENNSYLVANIA		19462		
Relationship:	Executi	ve Officer	\checkmark	Director		Promoter	
Clarification of Response (if Necessary)							

4. Industry Group

Banking & Financial Services

- Commercial Banking
- Insurance
- □ Investing
- Investment Banking
- Pooled Investment Fund

Other Banking & Financial Services

Business Services

Energy

- Coal Mining
- Electric Utilities
- Energy Conservation
- Environmental Services
- 🔲 Oil & Gas

5. Issuer Size

Other Energy

- 🗹 Biotechnology
- Health Insurance
- Hospitals & Physicians
- Pharmaceuticals
- Other Health Care

Manufacturing

Real Estate

Commercial

Construction

Residential

REITS & Finance

Other Real Estate

Restaurants

Technology

Computers

- Telecommunications
- Other Technology

Travel

- Airlines & Airports
- Lodging & Conventions
- Tourism & Travel Services

Other Travel

Other

J O	00001 0120				
Rever	nue Range	Aggrega	Aggregate Net Asset Value Range		
	No Revenues		No Aggregate Net Asset Value		
	\$1 - \$1,000,000		\$1 - \$5,000,000		
	\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000		
	\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000		
	\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000		
	Over \$100,000,000		Over \$100,000,000		
\checkmark	Decline to Disclose		Decline to Disclose		
	Not Applicable		Not Applicable		

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
Rule 504 (b)(1)(i)	₩ Rule 506
Rule 504 (b)(1)(ii)	Securities Act Section 4(6)
Rule 504 (b)(1)(iii)	□ Investment Company Act Section 3(c)



8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

🗌 Yes 🗹 No

9. Type(s) of Securities Offered (select all that apply)

Pooled Investment Fund
 Interests

🗹 Equity

Tenant-in-Common Securities	
-----------------------------	--

- **Mineral Property Securities**
- Debt

 \checkmark

- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or 🔲 Other (describe) Other Right to Acquire Security

10. Business Combination Transaction

Is this offering being made in connection with a business combination Yes No No transaction, such as a merger, acquisition or exchange offer?

Clarification of Response (if Necessary)

11. Minimum Investment

Minimum investment accepted from any outside \$ 5000 investor

12. Sales Compensation

Recipient	Recipient CRD Number 🔲 None
(Associated) Broker or Dealer 📃 None	(Associated) Broker or Dealer CRD Dealer CRD None
Street Address 1	Street Address 2
City State	/Province/Country ZIP/Postal Code
State(s) of Solicitation	All States

13. Offering and Sales Amounts

Total Offering Amount	\$	385000	USD	Indefinite			
Total Amount Sold	\$	385000	USD				
Total Remaining to be Sold	\$	0	USD	🔲 Indefinite			
Clarification of Response (if Necessary)							

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,



USD

Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

31			_	_
	31			

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$	0	USD	Estimate
Finders' Fees \$	0	USD	Estimate
Clarification of Response (if Necessary)			

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 0	USD	Estimate
Clarification of Response (if Necessary)			
Signature and Submission			

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that the Issuer is not disqualified from relying on any Regulation D exemption it has identified in Item 6 above for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
BioPharma	/S/ STEPHEN P. HARRINGTON	STEPHEN P. HARRINGTON	PRESIDENT	2013-07-25